Ensysce Biosciences, Inc. (ENSC)

Market Cap	3.61M
Revenue (ttm)	n/a
Net Income (ttm)	-11.55M
Shares Out	7.59M
EPS (ttm)	-3.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,204
Open	0.481
Previous Close	0.493
Day's Range	0.442 - 0.520
52-Week Range	0.442 - 2.340
Beta	0.87
Analysts	Strong Buy
Price Target	7.00 (+1,372.75%)
Earnings Date	Aug 9, 2024

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: ENSC

Analyst Forecast

According to one analyst, the rating for ENSC stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target

$7.0

(1,372.75% upside)

Analyst Consensus: Strong Buy